KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results.

Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo, Kulli Kingo

J Eur Acad Dermatol Venereol 40(4) 617-625

PMID41239909
PMCIDPMC13014435
DOI10.1111/jdv.70155
发表日期2025-11-15
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population. In a Phase 3 study (NCT02471144), secukinumab treatment for up to 104 weeks demonstrated good tolerability and efficacy in paediatric patients with severe chronic plaque psoriasis. OBJECTIVES: Final long-term safety and efficacy results of secukinumab through 236 weeks of treatment in paediatric patients with severe chronic plaque psoriasis. METHODS: During the extension period (Weeks 52-236), paediatric patients aged 6 to <18 years with severe chronic plaque psoriasis received either 'Any secukinumab' low dose (LD; patients receiving secukinumab LD up to Week 52; patients on placebo who transitioned to secukinumab LD) or 'Any secukinumab' high dose (HD; patients receiving secukinumab HD up to Week 52 and patients on placebo who transitioned to secukinumab HD). Assessments included Psoriasis Area and Severity Index (PASI) 75/90/100 responses, Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response, relapse, rebound, Children's Dermatology Life Quality Index (CDLQI) score, CDLQI 0/1 response and long-term safety up to Week 236. RESULTS: Secukinumab maintained efficacy through 236 weeks of treatment, with consistent responses observed in most assessments across both dose groups. At Week 236, the responder rate for IGA mod 2011 0/1 was 69.4% ('Any secukinumab' LD) and 79.5% ('Any secukinumab' HD); the PASI 75/90/100 responses were 97.2%/77.8%/50.0% ('Any secukinumab' LD) and 97.4%/84.6%/69.2% ('Any secukinumab' HD). CDLQI 0/1 responses remained consistent in both dose groups and were maintained up to Week 236 ('Any secukinumab' LD: 64.3%; 'Any secukinumab' HD: 67.7%). The most common adverse events were nasopharyngitis (EAIR/100 PYs [95% CI]:13.9 [10.0, 18.7]), headache (5.8 [3.7, 8.8]) and tonsillitis (4.7 [2.8, 7.4]). Candida infections were reported in 3 patients. CONCLUSIONS: These findings support the sustained efficacy and favourable safety profile of secukinumab in paediatric patients with severe plaque psoriasis over a 236-week treatment period.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1IGA mod 2011 0/1 and PASI responses up to Week 236 (a) IGA mod 2011 0/1 responses up to Week 236; (b) PASI 75 responses up to Week 236; (c) PASI 90 responses up to Week 236; (d) PASI 100 responses up to Week 236 using observed cases. N represents the number of patients in each treatment group included in the full analysis set. The ‘Any secukinumab’ LD group comprises patients originally randomized to secukinumab LD and patients from the placebo‐secukinumab LD group. The ‘Any secukinumab’ HD group comprises patients initially randomized to secukinumab HD and patients from the placebo‐secukinumab HD group. HD, high dose; IGA mod 2011, Investigator's Global Assessment modified 2011; LD, low dose; N , number of patients; PASI, Psoriasis Area and Severity Index; SEC, secukinumab.
非 KM Figure
FIGURE 2CDLQI response and scores up to Week 236 in LOCF analysis (a) CDLQI 0/1 response; (b) change from baseline in CDLQI total score. N represents the number of patients in each treatment group included in the full analysis set. The ‘Any secukinumab’ LD group comprises patients originally randomized to secukinumab LD and patients from the placebo‐secukinumab LD group. The ‘Any secukinumab’ HD group comprises patients initially randomized to secukinumab HD and patients from the placebo‐secukinumab HD group. CDLQI, Children's Dermatology Life Quality Index; HD, high dose; LD, low dose; LOCF, last observation carried forward. N represents the number of patients in each treatment group included in the full analysis set; SEC, secukinumab.
非 KM Figure